Anemia: Interpretation of the complete blood count

Article written and reviewed by Dr Luca Moretti

The complete blood count is the essential basis for the laboratory assessment of anemia. Although it is a routine test, it contains such a wealth of information that a superficial reading may lead to the loss of crucial diagnostic elements. Correct interpretation requires the ability to go beyond the mere numerical value, integrating quantitative and qualitative parameters with the clinical context, medical history and findings from physical examination. Together with clinical observation, the complete blood count is the tool that makes it possible to initiate rational differential reasoning, which is indispensable for guiding the subsequent choice of second-level investigations and establishing a truly targeted diagnostic strategy.

A frequent error is to focus exclusively on the hemoglobin value to define and monitor anemia. In reality, all erythrocyte parameters provide information that, when read in an integrated manner, allows identification of the underlying pathophysiological mechanism: impaired production, blood loss, hemolysis, or altered red blood cell morphology or function. The differential diagnosis of anemia begins precisely with this complex reading, in which the sequential nature of the reasoning process is more important than simple knowledge of threshold values.

Detailed analysis of erythrocyte parameters

The fundamental parameters of the complete blood count include:

• Hemoglobin (Hb): the central parameter; its reduction defines the presence of anemia according to threshold values that vary by age, sex and physiological conditions (pregnancy, childhood, older age). It is influenced both by the true red blood cell mass and by changes in blood volume (hemodilution or hemoconcentration). Particularly low values (about 7-8 g/dL) require urgent assessment, but do not by themselves determine the indication for transfusion: in hemodynamically stable hospitalized adults, restrictive strategies often consider transfusion when Hb is <7 g/dL, with different thresholds in specific clinical contexts. In acute myocardial infarction, the AABB 2025 guideline instead suggests a liberal strategy when Hb is <10 g/dL, with a conditional recommendation and low-certainty evidence.
• Hematocrit (HCT): reflects the proportion of blood volume made up of red blood cells. Rapid changes in blood volume, such as acute hemorrhage with subsequent plasma expansion, may mask or exaggerate the true extent of anemia. In some conditions, such as severe dehydration or gestosis with hemoconcentration, a high hematocrit may conceal a functional deficit.
• Red blood cell count (RBC): measures the absolute number of red blood cells per microliter of blood. The isolated value has limited interpretative meaning and must be read together with hemoglobin, MCV, RDW and the reticulocyte count. A reduced RBC count associated with a low reticulocyte count is typical of hypoproliferative forms.
• MCV (Mean Corpuscular Volume): mean corpuscular volume allows morphological classification of anemias into microcytic, normocytic and macrocytic forms. A reduced MCV (<80 fL) points toward iron deficiency or defects in hemoglobin synthesis, such as thalassemias; an increased MCV (>100 fL) may indicate megaloblastic forms due to impaired maturation (vitamin B12 or folate deficiency) or non-megaloblastic macrocytosis (for example, liver disease or certain drugs). Normocytic anemias may have numerous causes: kidney failure, chronic inflammation, acute hemorrhage and compensated hemolysis.
• MCH (Mean Corpuscular Hemoglobin) and MCHC (Mean Corpuscular Hemoglobin Concentration): represent, respectively, the mean amount and mean concentration of hemoglobin per red blood cell. Reduced MCH and MCHC indicate hypochromia, typical especially of iron deficiency and thalassemias. Increased MCHC is uncommon but may occur in some cases of hereditary spherocytosis.
• RDW (Red Cell Distribution Width): measures variability in red blood cell size (anisocytosis). A high RDW indicates the coexistence of red blood cells of different sizes, typical of deficiency anemias during treatment, some dysplastic forms, or the presence of dual populations (post-transfusion, myelodysplastic syndromes). A normal RDW does not exclude a deficiency and does not by itself identify the mechanism of anemia.

A sequential and contextualized analysis of these indices allows robust classification of anemia and helps hypothesize the predominant pathophysiological mechanism, guiding the selection of subsequent tests.

Reticulocytes: a window onto erythropoietic production

Reticulocytes are young red blood cells that have just been released into the circulation from the bone marrow. Their count is the best indicator of the marrow’s ability to respond to the demand for red blood cells and, consequently, makes it possible to distinguish anemias due to reduced production, whether hyporegenerative or aregenerative, from those secondary to blood loss or increased destruction.

It is essential to distinguish the relative value, meaning the percentage of total red blood cells, from the absolute value, meaning the number per microliter; the absolute count is generally preferred in anemia. The reticulocyte percentage must be corrected for the degree of anemia. The formula reticulocyte % × (patient Hct/normal Hct) provides the corrected reticulocyte percentage; the reticulocyte production index also requires correction for reticulocyte maturation time, which increases in more severe anemia.

• Low reticulocytes: typical of hypoproliferative anemias, such as bone marrow aplasia, nutritional deficiencies, chronic kidney disease and myelodysplasia, in which the marrow is unable to compensate for red blood cell loss.
• High reticulocytes: a sign of an effective erythropoietic response to increased demand, typical of acute hemorrhage or hemolysis. No isolated absolute threshold by itself confirms adequate regeneration: the value must be interpreted in relation to hemoglobin and, if necessary, by means of the reticulocyte production index.

During hematopoietic recovery, for example after iron or vitamin replacement, the reticulocyte count is one of the first parameters to increase, often before a significant increase in hemoglobin.

Conversely, an inappropriately low reticulocyte response usually points to reduced production, but it may also be observed very early in hemorrhage or hemolysis and in mixed mechanisms; it must therefore be interpreted in context.

Peripheral blood smear: morphological diagnostics

The peripheral blood smear completes the automated complete blood count by offering an essential qualitative assessment. It allows direct analysis of red blood cell morphology, identification of pathological elements such as blasts, immature cells and cytoplasmic inclusions, detection of abnormalities in other cell lines and recognition of dysmorphic cells, which often suggest the diagnosis.

• Anisocytosis and poikilocytosis: typical of deficiency anemias, myelodysplastic anemias, thalassemic forms and post-transfusion settings.
• Microcytes, marked hypochromia: indicative of iron deficiency, thalassemia or some forms of sideroblastic anemia.
• Macrocytes, particularly macro-ovalocytes: common in megaloblastic anemias due to vitamin B12 or folate deficiency. In liver disease and hypothyroidism, non-megaloblastic macrocytosis may occur, generally with round macrocytes.
• Spherocytes and elliptocytes: may suggest hereditary membrane disorders, although they are not exclusive to them. Target cells are observed especially in thalassemias, hemoglobinopathies, liver disease and after splenectomy.
• Schistocytes (red blood cell fragments): a typical sign of microangiopathic hemolytic anemia, including thrombotic thrombocytopenic purpura, hemolytic uremic syndrome and DIC.
• Presence of blasts, proerythroblasts or other immature cells: may indicate leukemia, myelodysplasia, bone marrow infiltration or an intense erythroid response and requires urgent interpretation in the clinical context.
• Howell-Jolly bodies: associated especially with hypo/asplenia. Basophilic stippling: associated with altered erythropoiesis/maturation, for example thalassemias, lead poisoning, megaloblastic anemia or MDS.

Smear examination is irreplaceable for recognizing complex or atypical patterns in which the complete blood count may be misleading or poorly informative. It should be requested in all unexplained anemias or when clinical findings are discordant.

Integrated diagnostics and limitations of the complete blood count

The interpretation of complete blood count data must always be integrated with the clinical history, drug history, objective findings and any chronic or acute diseases that may influence hematological parameters. Some conditions may alter the results:

• Pseudocytopenias: sample clotting, difficult collection, contamination from an infusion line or in-vitro cell aggregation may produce artefactual counts; platelet clumping is often EDTA-dependent.
• Preanalytical errors: in vitro hemolysis, contamination by fluids or substances, and storage errors may distort the data.
• Drug effects: chemotherapeutic agents and immunosuppressants may reduce erythrocyte production or, in some cases, promote hemolysis; anticoagulants may contribute to anemia mainly by increasing the risk of bleeding.
• Physiological changes: pregnancy, growth and aging modify reference values and must always be considered during interpretation.

The automated complete blood count has limitations in distinguishing some morphological abnormalities, such as microcytosis due to thalassemia versus iron deficiency or the presence of undetected dysmorphic cells; for this reason, correlation with the clinical picture and the peripheral blood smear remains essential.

In cases of pancytopenia or multiple abnormalities of blood cell lines, such as anemia associated with leukopenia and/or thrombocytopenia, the indication for bone marrow investigations is strengthened, especially if clinical signs of infiltration, splenomegaly or refractoriness to conventional therapies appear.

From the complete blood count to second-level investigations

Accurate interpretation of the complete blood count and related indices makes it possible to rationally select the most appropriate second-level investigations, limiting unnecessary testing and optimizing the diagnostic pathway. Subsequent choices are guided by the identified pattern:

• Microcytic pattern: assessment of iron metabolism (ferritin, serum iron, transferrin and transferrin saturation) and, if the pattern is not explained by iron status, study of hemoglobin fractions by HPLC or electrophoresis, with targeted genetic analyses when indicated.
• Macrocytic pattern: measurement of vitamin B12 and folate levels, testing for liver and thyroid disease, possible identification of myelotoxic drugs or bone marrow investigations.
• Normocytic pattern: assessment of renal function, inflammatory markers, search for causes of acute or chronic blood loss and investigations for chronic systemic diseases.
• Suspected hemolysis: measurement of lactate dehydrogenase (LDH), indirect bilirubin and haptoglobin, together with the reticulocyte count and peripheral smear; a direct antiglobulin test is added when an immune mechanism is suspected, while further tests depend on the clinical context.
• Abnormalities of red blood cell morphology: genetic investigations, red blood cell membrane studies, enzyme studies or specific functional tests.
• Complex patterns: in cases of anemia associated with leukopenia and thrombocytopenia, bone marrow aspiration and/or bone marrow biopsy to exclude myelodysplasia, leukemia or neoplastic infiltration.

All these pathways will be detailed in the pages dedicated to the individual forms of anemia, with a description of diagnostic strategies, interpretative pitfalls and the clinical-laboratory criteria useful for a precise differential diagnosis.

The complete blood count therefore represents the obligatory entry point into the anemia algorithm: its correct interpretation allows timely diagnoses, helps avoid errors and enables the rapid establishment of appropriate therapy. However, each datum must always be placed within the patient’s overall context, considering the full set of clinical and instrumental variables.

References
1. Tefferi A. Anemia in adults: a contemporary approach to diagnosis. Mayo Clin Proc. 2003;78(10):1274–1280.
2. Kaushansky K, Lichtman MA, Prchal JT, Levi M, Burns LJ, Linch DC. Williams Hematology. McGraw-Hill Education. 10th ed. 2021.
3. Hoffbrand AV, Higgs DR, Keeling DM, Mehta AB. Postgraduate Haematology. Wiley-Blackwell. 7th ed. 2016.
4. Weiss G, Goodnough LT. Anemia of chronic disease. New England Journal of Medicine. 2005;352(10):1011-1023.
5. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509-2519.
6. Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372(19):1832–1843.
7. Heeney MM, Finberg KE. Iron-refractory iron deficiency anemia (IRIDA). Hematol Oncol Clin North Am. 2014;28(4):637–652.
8. Green R, Allen LH, Bjørke-Monsen AL, et al. Vitamin B12 deficiency. Nat Rev Dis Primers. 2017;3:17040.
9. Hoffman R, Benz EJ Jr, Silberstein LE, et al. Hematology: Basic Principles and Practice. Elsevier. 7th ed. 2018.
10. Bain BJ. Blood Cells: A Practical Guide. Wiley-Blackwell. 5th ed. 2015.
11. Carson JL, Stanworth SJ, Guyatt G, et al. Red blood cell transfusion: 2023 AABB international guidelines. JAMA. 2023;330(19):1892–1902.
12. Pagano MB, Stanworth SJ, Dennis J, et al. Red Cell Transfusion in Acute Myocardial Infarction: AABB International Clinical Practice Guidelines. Ann Intern Med. 2025;178(10):1469–1477. doi:10.7326/ANNALS-25-00706.